Abstract
A detailed stability testing of solid state imidapril hydrochloride (IMD) was performed and its degradation products were identified. The analysis was conducted according to ICH guidelines Q1A(R2). Pure IMD samples were exposed to stress conditions of elevated temperature and relative humidity (T = 363 K, RH = 76.4%) in order to accelerate degradation. The regular loss of IMD content with time, and the formation of two degradation impurities were observed. The appropriate reaction rate constants k (for IMD degradation and for the formation of product I and II) were calculated using Prout-Tompkins equation. The obtained degradation products were separated and identified by means of LC-MS technique. Based on the obtained m/z values, the masses and the structures of the formed degradation impurities were established. Also IMD degradation scheme was constructed. It was demonstrated that under the applied analytical conditions, IMD degradation follows an autocatalytic reaction model with the rate constant k = (4.764 ± 0.34)×10 −6 s −1 and with the parallel formation of two degradation products: imidaprilat and the diketopiperazine derivative. The obtained experimental results are in agreement with IMD degradation pathways proposed theoretically.
Similar content being viewed by others
References
K. Hayashi, K. Nunami, J. Kato, N. Yoneda, M. Kubo, T. Ochiai, R. Ishida, J. Med. Chem. 32, 289 (1989)
D.M. Robinson, M.P. Curran, K.A. Lyseng-Williamson, Drugs 67, 1359 (2008)
M. Matsuoka, S. Horimoto, M. Mabuchi, K. Banno, J. Chromatogr. 581, 65 (1992)
Supplement II to the Japanese Pharmacopoeia Fifteenth Edition, October 1st, 2009, Imidapril hydrochloride Monograph
B. Stanisz, K. Regulska, K. Kolasa, Acta Polon. Pharm. 68, 645 (2011)
B. Stanisz, K. Regulska, J. Kania, P. Garbacki, Drug Dev. Ind. Pharm. 39, 51 (2013)
L. Gu, R.G. Strickley, Pharm. Res. 4, 392 (1987)
M.L. Cotton, D.W. Wu, E.B. Vadas, Int. J. Pharm. 40, 129 (1987)
Y. Guo, S.R. Byrn, G. Zografi, J. Pharm. Sci. 89, 128 (2000)
Draft Guidance for Industry, Stability Testing of Drug Substances and Drug Products (FDA, Rockville, MD, 1998)
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for human use, ICH Harmonized Tripartite Guideline; Stability testing of new Drug substances and Products Q1A (R2), Step 5, ICH, Geneva, 2003
Stability testing of active substances and pharmaceutical products, Working document QAS/06.179, Draft 2.0, 19 April 2006
W. Zhou, R.K.J. Gilpin, Pharm. Sci. 93, 1545 (2004)
M. Matsuoka, S. Horimoto, M. Mabuchi, K. Banno, J. Chromatogr. 58, 65 (1992)
K. Yamanaka, S. Morikawa, K. Murata, et. al., J. Pharm. Biomed. Anal. 14, 281 (1996)
M. Starek, M. Dąbrowska, Cent. Eur. J. Chem. 10, 711 (2012)
J. Cielecka-Piontek, A. Lunzer, A. Jelińska, Cent. Eur. J. Chem. 9, 35 (2011)
P. Zalewski, J. Cielecka-Piontek, A. Jelińska, Cent. Eur J. Chem. 10, 121 (2012)
R. Skibiński, Cent. Eur J. Chem. 10, 232 (2012)
L.R. Snyder, J.J. Kirkland, J.L. Glajch (Eds), Practical HPLC Method Development, (Wiley-Interscience, New York, 1988) 402–438
Validation of analytical procedures, Proceeding of the International Conference of Harmonisation (ICH) (Commission of the European Communities, 2009)
E. Pawełczyk, T. Hermann, The Fundamentals of stability drugs (PZWL, Warsaw, 2006) (in Polish)
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Regulska, K., Stanisz, B. Kinetics and mechanism of solid state imidapril hydrochloride degradation and its degradation impurities identification. cent.eur.j.chem. 11, 754–762 (2013). https://doi.org/10.2478/s11532-013-0212-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2478/s11532-013-0212-9